← Back to calculator

Limited human topical data; no validated injectable dose

GHK-Cu

GHK-Cu

A plain-English reference on GHK-Cu — what it is, its unestablished injectable regulatory status, and the FDA's aggregation, impurity, and immunogenicity safety concerns for compounded copper peptides.

Peptide Calculator X

Reconstitution / draw volume / syringe units / supply-chain

Arithmetic + reference toolNot medical advice
Inputs
Limited / no data
Product form
Target dose
Weight unit
Syringe barrel
Draw to
50units
0.5 mL5 mg/mL2.5 mg / dose
1 mL syringe - 100 u/mLFits
50 u050100 u
ARITHMETIC OK - VERIFY CLINICALLY

Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.

10 mg
4
0 mg
28 days
-
-

Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.

Reconstitution planner

Reverse: pick a dose and the units you want it to read, then calculate diluent to add.

Reverse
Desired dose
1 mL
10 mg/mL
4
Formula and source context only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol. Do not use this tool to infer sterility, potency, purity, stability, compatibility, or an appropriate dose. Catalog and supply-chain data: finnrick.com/products - research date 2026-06-24.

GHK-Cu: reference record

GHK-Cu - regulatory status, route, frequency and published range
Regulatory statusNo FDA-approved injectable product; FDA reports limited injectable safety data
RouteNo established injectable treatment route
Dosing frequencyNo established regimen
Published rangeNo established range
Evidence basisLimited human topical data; no validated injectable dose
Common vial sizes50, 100

Sources

What is GHK-Cu?

GHK-Cu is a copper-binding tripeptide, glycyl-L-histidyl-L-lysine complexed with copper. Most of the human evidence behind it concerns topical cosmetic use, which is a fundamentally different exposure from injection.

Is GHK-Cu FDA-approved?

No. There is no FDA-approved injectable GHK-Cu product, and the FDA has reported limited injectable safety data. Cosmetic topical availability is not an approval for injectable use.

How is GHK-Cu given?

There is no established injectable treatment route and no established regimen. No clinically validated injectable dose has been identified.

What are the known safety concerns with GHK-Cu?

Topical and cosmetic evidence must not be extrapolated to injection. The FDA has raised aggregation, impurity and immunogenicity concerns for compounded copper-peptide preparations.

No clinically validated injectable dose identified

No default dose; calculator accepts manual protocol inputs only.

Topical/cosmetic evidence must not be extrapolated to injection; FDA notes aggregation, impurities and immunogenicity concerns.

Supply-chain quality · Finnrick

Avg quality score

7

/10

Purity range

99.6

99.97

%

Qty divergence

±

48

%

Vendors · samples

67

·

544

Common vial sizes

50, 100

mg

Test window

Apr 2025 - Jun 2026

Related calculators & comparisons

Browse all peptides →